Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians<sup>#</sup>

Jentes, Emily S.; Lash, R. Ryan; Johansson, Michael A.; Sharp, Tyler M.; Henry, Ronnie; Brady, Oliver J.; Sotir, Mark J.; Hay, Simon I.; Margolis, Harold S.; Brunette, Gary W.

doi:10.1093/jtm/taw062

Cited by 92 publications

(62 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our efforts are directed towards the development of a vaccine against dengue virus (DENV). DENV infection is the leading cause of mosquito‐borne illness throughout the tropical world, where an estimated 2.5 billion people live at risk of infection each year . Travelers to dengue endemic countries are also at risk of disease and facilitating viral transmission .…”

Section: Introductionmentioning

confidence: 99%

“…5,6 Travelers to dengue endemic countries are also at risk of disease and facilitating viral transmission. 6,7 Since the isolation of DENV in 1943, the development of an effective vaccine that provides balanced, long-lasting immunity has been challenging. This is partly due to the complexity of dengue epidemiology, population immunity, and the interplay between viral pathogenesis and host immunological mechanisms.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Microneedle‐based intradermal delivery of stabilized dengue virus

Turvey

Uppu

Sharif

et al. 2019

Bioengineering & Transla Med

View full text Add to dashboard Cite

Current live‐attenuated dengue vaccines require strict cold chain storage. Methods to preserve dengue virus (DENV) viability, which enable vaccines to be transported and administered at ambient temperatures, will be decisive towards the implementation of affordable global vaccination schemes with broad immunization coverage in resource‐limited areas. We have developed a microneedle (MN)‐based vaccine platform for the stabilization and intradermal delivery of live DENV from minimally invasive skin patches. Dengue virus‐stabilized microneedle arrays (VSMN) were fabricated using saccharide‐based formulation of virus and could be stored dry at ambient temperature up to 3 weeks with maintained virus viability. Following intradermal vaccination, VSMN‐delivered DENV was shown to elicit strong neutralizing antibody responses and protection from viral challenge, comparable to that of the conventional liquid vaccine administered subcutaneously. This work supports the potential for MN‐based dengue vaccine technology and the progression towards cold chain‐independence. Dengue virus can be stabilized using saccharide‐based formulations and coated on microneedle array vaccine patches for storage in dry state with preserved viability at ambient temperature (VSMN; virus‐stabilized microneedle arrays).

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Microneedle‐based intradermal delivery of stabilized dengue virus

Turvey

Uppu

Sharif

et al. 2019

Bioengineering & Transla Med

View full text Add to dashboard Cite

show abstract

“…In 2012, the first major European outbreak of dengue occurred in Madeira [40]. International travellers are increasingly at risk of dengue [2,41–44], with attack rates reported as high as 5.51 cases per 1,000 travel-months to endemic areas [45]. Dengue is now the leading cause of fever in returning travellers, having overtaken malaria for travellers to South East Asia [46].…”

Section: Research Areamentioning

confidence: 99%

“…Despite the increasing global burden of dengue both in terms of annual incidence and geographic distribution [1,2], dengue remains a neglected disease [3]. In 2010, the European Commission launched a Seventh Framework Programme call entitled ‘Comprehensive control of dengue under changing climatic conditions’.…”

Section: Introductionmentioning

confidence: 99%

Novel tools for the surveillance and control of dengue: findings by the DengueTools research consortium

Wilder‐Smith

Tissera

AbuBakar

et al. 2018

Global Health Action

View full text Add to dashboard Cite

Background: Dengue fever persists as a major global disease burden, and may increase as a consequence of climate change. Along with other measures, research actions to improve diagnosis, surveillance, prevention, and predictive models are highly relevant. The European Commission funded the DengueTools consortium to lead a major initiative in these areas, and this review synthesises the outputs and findings of this work conducted from 2011 to 2016. Research areas: DengueTools organised its work into three research areas, namely [1] Early warning and surveillance systems; [2] Strategies to prevent dengue in children; and [3] Predictive models for the global spread of dengue.Research area 1 focused on case-studies undertaken in Sri Lanka, including developing laboratory-based sentinel surveillance, evaluating economic impact, identifying drivers of transmission intensity, evaluating outbreak prediction capacity and developing diagnostic capacity. Research area 2 addressed preventing dengue transmission in school children, with case-studies undertaken in Thailand. Insecticide-treated school uniforms represented an intriguing potential approach, with some encouraging results, but which were overshadowed by a lack of persistence of insecticide on the uniforms with repeated washing. Research area 3 evaluated potential global spread of dengue, particularly into dengue-naïve areas such as Europe. The role of international travel, changing boundaries of vectors, developing models of vectorial capacity under different climate change scenarios and strategies for vector control in outbreaks was all evaluated. Concluding remarks: DengueTools was able to make significant advances in methods for understanding and controlling dengue transmission in a range of settings. These will have implications for public health agendas to counteract dengue, including vaccination programmes. Outlook: Towards the end of the DengueTools project, Zika virus emerged as an unexpected epidemic in the central and southern America. Given the similarities between the dengue and Zika viruses, with vectors in common, some of the DengueTools thinking translated readily into the Zika situation.

show abstract

“…A safe and effective dengue vaccine could have a major public health impact, as dengue causes approximately 9,000 deaths and between 50-100 million clinically apparent cases worldwide every year [1,2] and has a growing geographic distribution [3]. The first licensed dengue vaccine, CYD-TDV (Dengvaxia®), is a tetravalent, live-attenuated vaccine that was licensed in multiple countries after demonstrating efficacy against symptomatic disease in phase-III trials [4,5].…”

Section: Introductionmentioning

confidence: 99%

Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure

España

Yao

Anderson

et al. 2018

Preprint

View full text Add to dashboard Cite

The tetravalent dengue vaccine CYD-TDV (Dengvaxia®) is the first licensed vaccine against dengue, but recent findings indicate an elevated risk of severe disease among vaccinees without prior dengue virus (DENV) exposure. The World Health Organization currently recommends CYD-TDV only for individuals with serological confirmation of past DENV exposure. Our objective was to evaluate the potential impact and cost-effectiveness of vaccination following serological screening. We used an agent-based model to simulate DENV transmission over a 30-year timeframe, with and without vaccination. We considered a range of values for the proportion of vaccinees with prior DENV exposure. We projected the proportion of symptomatic and hospitalized cases averted as a function of the sensitivity and specificity of serological screening. We evaluated the cost-effectiveness of screening and vaccination under economic scenarios representative of Brazil and the Philippines. We found that public health impact depended primarily on the sensitivity of serological screening in high-transmission settings and on a combination of sensitivity and specificity in low-transmission settings. Reducing risk from an individual perspective required high specificity, no less than 0.8. Cost-effectiveness could be achievable from the perspective of a public payer provided that screening sensitivity for prior DENV exposure and the value of a disability-adjusted life-year were both high. Costeffectiveness was also achievable from an individual perspective, particularly with high screening specificity and low coverage. Whereas the results of this analysis offer general guidelines about CYD-TDV vaccination, decisions in specific contexts would benefit from additional, more context-specific modeling analyses. Vaccination with CYD-TDV following serological screening could have a positive impact in certain epidemiological settings, provided that screening is highly specific, at least moderately sensitive, and inexpensive.. CC-BY-NC-ND 4.0 International license It is made available under a was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint (which . http://dx.doi.org/10.1101/367060 doi: bioRxiv preprint first posted online Jul. 11, 2018; 2 INTRODUCTION A safe and effective dengue vaccine could have a major public health impact, as dengue causes approximately 9,000 deaths and between 50-100 million clinically apparent cases worldwide every year [1,2], with increasing geographic distribution [3]. The first licensed dengue vaccine, CYD-TDV (Dengvaxia®), is a tetravalent, live-attenuated vaccine that was licensed in multiple countries after demonstrating efficacy against symptomatic disease in phase-III trials [4,5]. Protection has been hypothesized to derive primarily from the vaccine functioning as a "silent infection" [6]. Following their first natural infection subsequent to vaccination, this mechanism would result in vaccinees with prior dengue v...

show abstract

Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians^#

Cited by 92 publications

References 14 publications

Microneedle‐based intradermal delivery of stabilized dengue virus

Microneedle‐based intradermal delivery of stabilized dengue virus

Novel tools for the surveillance and control of dengue: findings by the DengueTools research consortium

Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure

Contact Info

Product

Resources

About

Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians#

Cited by 92 publications

References 14 publications

Microneedle‐based intradermal delivery of stabilized dengue virus

Microneedle‐based intradermal delivery of stabilized dengue virus

Novel tools for the surveillance and control of dengue: findings by the DengueTools research consortium

Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure

Contact Info

Product

Resources

About

Evidence-based risk assessment and communication: a new global dengue-risk map for travellers and clinicians^#